Core Viewpoint - A class action securities lawsuit has been filed against Integer Holdings Corporation, alleging securities fraud that affected investors between July 25, 2024, and October 22, 2025 [1][2]. Group 1: Allegations of Fraud - The lawsuit claims that Integer Holdings Corporation materially overstated its competitive position in the electrophysiology manufacturing market [2]. - It is alleged that despite claims of strong visibility into customer demand, the company was experiencing a sustained deterioration in sales related to two of its electrophysiology devices [2]. - The complaint further asserts that Integer mischaracterized its electrophysiology devices as a long-term growth driver for its cardio & vascular segment, leading to materially false and misleading statements about the company's business and prospects [2]. Group 2: Legal Process and Participation - Investors who suffered losses during the relevant time frame have until February 9, 2026, to request to be appointed as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, with no obligation to participate [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a track record of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4].

Core Viewpoint - A class action lawsuit has been filed against Integer Holdings Corporation for allegedly making misleading statements and failing to disclose material adverse facts about its business during the specified Class Period [1][3]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who acquired Integer securities from July 25, 2024, to October 22, 2025 [1][2]. - Investors have until February 9, 2026, to seek appointment as lead plaintiff representatives [2]. Group 2: Allegations Against the Company - The complaint alleges that Integer overstated its competitive position and did not adequately disclose sales deterioration in its electrophysiology devices [3]. - The lawsuit claims that the company mischaracterized its growth drivers [3]. - The truth about the company's performance began to emerge on October 23, 2025, when it reduced its sales guidance, leading to a stock price decline of $35.22 per share, over 32% in a single trading day [3].

Core Viewpoint - A class action lawsuit has been filed against Integer Holdings Corporation and its senior executives for securities fraud following a significant drop in stock price due to alleged violations of federal securities laws [1][3]. Company Overview - Integer Holdings Corporation specializes in designing and manufacturing cardiac rhythm management and cardiovascular products, including electrophysiology devices that diagnose and treat arrhythmias [4]. Allegations of Securities Fraud - The lawsuit claims that Integer misrepresented the demand and revenue for its electrophysiology products, which had reportedly fallen sharply, contradicting the company's public statements about sales growth and market position [4][5]. Stock Price Decline - On October 23, 2025, Integer revised its 2025 sales guidance down to a range of $1.840 billion to $1.854 billion from a previous range of $1.850 billion to $1.876 billion, which was below analysts' expectations. The company also projected a net sales growth of -2% to 2% and organic sales growth of 0% to 4% for 2026. This announcement led to a stock price drop of $35.22 per share, or over 32%, from $109.11 to $73.89 [6].

Core Viewpoint - A class action lawsuit has been filed against Integer Holdings Corporation and its senior executives for securities fraud following a significant drop in stock price due to alleged violations of federal securities laws [1]. Company Overview - Integer Holdings Corporation specializes in designing and manufacturing cardiac rhythm management and cardiovascular products, including electrophysiology devices that diagnose and treat arrhythmias [4]. Allegations of Securities Fraud - The lawsuit claims that Integer misrepresented the demand and revenue for its electrophysiology products, which had reportedly fallen sharply, contradicting the company's public statements about sales growth and market position [5][4]. Stock Price Decline - On October 23, 2025, Integer revised its 2025 sales guidance down to a range of $1.840 billion to $1.854 billion from a previous range of $1.850 billion to $1.876 billion, which was below analysts' expectations. The company also projected a net sales growth of -2% to 2% and organic sales growth of 0% to 4% for 2026. This announcement led to a stock price drop of $35.22 per share, or over 32%, from $109.11 to $73.89 [6].

Core Viewpoint - Integer Holdings Corporation is facing a securities fraud class action lawsuit alleging misrepresentations about its market position and overstated demand for its electrophysiology devices [4][5]. Group 1: Lawsuit Details - The lawsuit was filed in the United States District Court for the Southern District of New York on behalf of investors who purchased or acquired Integer common stock between July 25, 2024, and October 22, 2025 [4]. - The allegations include violations of the Securities Exchange Act of 1934 against the Company and certain senior officers [4]. Group 2: Investor Information - Investors wishing to serve as lead plaintiff must file papers by February 9, 2026, with the option to remain an absent class member if they choose not to take action [6]. - All representation in the lawsuit is on a contingency fee basis, meaning shareholders pay no fees or expenses [6]. Group 3: Law Firm Background - Bernstein Liebhard LLP has recovered over $3.5 billion for its clients since 1993 and has been recognized for its success in litigating class actions [7].

NEW YORK, Jan. 8, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Integer Holdings Corporation (NYSE: ITGR). Shareholders who purchased shares of ITGR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE:https://securitiesclasslaw.com/securities/integer-holdings-corporation-loss-submission-form/?id=182850&from=4  CLASS P ...

Core Viewpoint - Class action lawsuits have been filed on behalf of shareholders of several publicly-traded companies, with specific deadlines for filing lead plaintiff motions [1] Group 1: Bitdeer Technologies Group (NASDAQ: BTDR) - Class period is from June 6, 2024, to November 10, 2025, with a lead plaintiff deadline of February 2, 2026 [2] - Allegations include false and misleading statements regarding the SEAL04 chip's energy efficiency and its readiness for mass production, impacting the company's business outlook [2] Group 2: Gauzy Ltd. (NASDAQ: GAUZ) - Class period is from March 11, 2025, to November 13, 2025, with a lead plaintiff deadline of February 6, 2026 [3] - Allegations state that three French subsidiaries lacked financial means to meet debts, indicating potential insolvency and default risks, which misled investors about the company's financial health [3] Group 3: Integer Holdings Corporation (NYSE: ITGR) - Class period is from July 25, 2024, to October 22, 2025, with a lead plaintiff deadline of February 9, 2026 [4] - Allegations include overstating competitive position in the EP manufacturing market and mischaracterizing sales deterioration, leading to misleading statements about growth prospects [4] Group 4: F5, Inc. (NASDAQ: FFIV) - Class period is from October 28, 2024, to October 27, 2025, with a lead plaintiff deadline of February 17, 2026 [5] - Allegations involve a significant security incident that jeopardized client security and the company's future, resulting in misleading statements about business operations [5]

Philadelphia, Pennsylvania--(Newsfile Corp. - January 7, 2026) - National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against Integer Holdings Corporation (NYSE: ITGR) ("Integer" or the "Company") on behalf of investors who purchased or otherwise acquired Integer securities during the period of July 25, 2024 through October 22, 2025 (the "Class Period"), inclusive.Investor Deadline: Investors who purchased Integer securities during the Class Period may, no l ...

Core Viewpoint - A class action lawsuit has been filed against Integer Holdings Corporation and its senior executives for securities fraud following a significant drop in stock price due to alleged violations of federal securities laws [1][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of New York, titled West Palm Beach Firefighters' Pension Fund v. Integer Holdings Corporation, et al., No. 1:25-cv-10251 [3]. - Investors have until February 9, 2026, to request to be appointed to lead the case [3]. Group 2: Company Performance and Allegations - Integer designs and manufactures cardiac rhythm management and cardiovascular products, including electrophysiology devices [4]. - The company allegedly overstated demand for its EP devices while public assurances contradicted the reality of falling demand and revenue [5]. - On October 23, 2025, Integer lowered its 2025 sales guidance to between $1.840 billion and $1.854 billion, down from a previous range of $1.850 billion to $1.876 billion, which was below analysts' expectations [6]. Group 3: Stock Impact - Following the announcement of lowered sales guidance, Integer's stock price dropped by $35.22 per share, or over 32%, from $109.11 on October 22, 2025, to $73.89 on October 23, 2025 [6].

Core Viewpoint - A class action lawsuit has been filed against Integer Holdings Corporation and its senior executives for securities fraud following a significant drop in stock price due to alleged violations of federal securities laws [1]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of New York, titled West Palm Beach Firefighters' Pension Fund v. Integer Holdings Corporation, et al., No. 1:25-cv-10251 [3]. - Investors have until February 9, 2026, to request to be appointed to lead the case [3]. Group 2: Company Background - Integer Holdings Corporation designs and manufactures cardiac rhythm management and cardiovascular products, including electrophysiology devices that diagnose and treat arrhythmias [4]. - The company had previously claimed strong sales growth and market position for its electrophysiology devices, which is now being challenged [4]. Group 3: Financial Performance - Integer's stock price dropped by $35.22 per share, or over 32%, from $109.11 on October 22, 2025, to $73.89 on October 23, 2025, following the announcement of lowered sales guidance [6]. - The company revised its 2025 sales guidance to a range of $1.840 billion to $1.854 billion, down from $1.850 billion to $1.876 billion, which was below analysts' expectations [6]. - Integer also projected poor net sales growth of -2% to 2% and organic sales growth of 0% to 4% for 2026, citing slower adoption of two of its electrophysiology devices [6][5].